Can AstraZeneca's Motavizumab Leapfrog Synagis? Advisory Committee Will Weigh In
This article was originally published in The Pink Sheet Daily
Executive Summary
Panel meeting on the respiratory syncytial virus product - which demonstrated non-inferiority, but not superiority, to Synagis - is set for June 2.